notable names include research groups in cited literature

Notable Labs is a clinical-stage precision oncology company that leverages its proprietary Predictive Precision Medicine Platform (PPMP) to identify the most effective therapies for cancer patients. The platform uses high-throughput screening of patient-derived primary cells to predict clinical responses with high accuracy, effectively acting as an 'ex vivo' clinical trial. By focusing on patients most likely to respond to specific treatments, Notable aims to accelerate drug development and improve patient outcomes in hematologic malignancies. The company's lead program is currently evaluating Volasertib in patients with relapsed or refractory acute myeloid leukemia.